9.82

4.69% +0.44

Pulmonx Corp (LUNG)

Overview News Price History Option Chain Financials Discussions Forecast

Pulmonx Corp stock is currently priced at $9.82, with a 24-hour trading volume of 709.28K. It has seen a +4.69% increased in the last 24 hours and a +23.52% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $9.40 pivot point. If it approaches the $9.96 resistance level, significant changes may occur.

Previous Close:

$9.38

Open:

$9.55

24h Volume:

709.28K

Market Cap:

$381.13M

Revenue:

$68.68M

Net Income/Loss:

$-60.84M

P/E Ratio:

-6.0994

EPS:

-1.61

Net Cash Flow:

$-38.42M

1W Performance:

+34.89%

1M Performance:

+23.52%

6M Performance:

-1.01%

1Y Performance:

-21.19%

1D Range:

$9.55

$9.8899

52W Range:

$7.11

$14.84

Pulmonx Corp Stock (LUNG) Company Profile

Name

Pulmonx Corp

Sector

Healthcare (1213)

Industry

Medical Devices (160)

Phone

650-364-0400

Address

700 Chesapeake Drive, Redwood City

Employee

202

Twitter

Next Earnings Date

2024-05-16

Latest SEC Filings

LUNG's Discussions on Twitter

Pulmonx Corp Stock (LUNG) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-05-23	Initiated	Craig Hallum	Buy
Feb-27-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Jan-03-23	Downgrade	BofA Securities	Neutral → Underperform
Dec-12-22	Upgrade	Citigroup	Neutral → Buy
Jul-11-22	Downgrade	Citigroup	Buy → Neutral
Mar-02-22	Resumed	BofA Securities	Neutral
Dec-08-21	Upgrade	Piper Sandler	Neutral → Overweight
Apr-01-21	Initiated	Citigroup	Buy
Mar-25-21	Initiated	Piper Sandler	Neutral
Mar-10-21	Upgrade	BofA Securities	Neutral → Buy
Jan-04-21	Downgrade	BofA Securities	Buy → Neutral
Oct-26-20	Initiated	BofA Securities	Buy
Oct-26-20	Initiated	Canaccord Genuity	Buy
Oct-26-20	Initiated	Morgan Stanley	Equal-Weight
Oct-26-20	Initiated	Stifel	Buy
Oct-26-20	Initiated	Wells Fargo	Equal Weight

View All

Pulmonx Corp Stock (LUNG) Latest News

Pulmonx Corp Stock (LUNG) Financials Data

Pulmonx Corp (LUNG) Revenue 2024

LUNG reported a revenue (TTM) of $68.67 million for the quarter ending December 31, 2023, a +27.98% rise year-over-year.

Pulmonx Corp (LUNG) Net Income 2024

LUNG net income (TTM) was -$60.84 million for the quarter ending December 31, 2023, a -3.26% decrease year-over-year.

Pulmonx Corp (LUNG) Cash Flow 2024

LUNG recorded a free cash flow (TTM) of -$38.42 million for the quarter ending December 31, 2023, a +17.21% increase year-over-year.

Pulmonx Corp (LUNG) Earnings per Share 2024

LUNG earnings per share (TTM) was -$1.60 for the quarter ending December 31, 2023, a -0.63% decline year-over-year.

Pulmonx Corp Stock (LUNG) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Rose Geoffrey Beran	CHIEF COMMERCIAL OFFICER	Mar 22 '24	Sale	9.36	1,184	11,082	307,868
French Glendon E. III	PRESIDENT AND CEO	Mar 01 '24	Sale	9.06	6,954	63,003	1,116,758
Lehman David Aaron	GENERAL COUNSEL	Mar 01 '24	Sale	9.06	4,351	39,420	145,488
Rose Geoffrey Beran	CHIEF COMMERCIAL OFFICER	Mar 01 '24	Sale	9.06	3,097	28,059	239,952
McKune John	INTERIM CFO	Mar 01 '24	Sale	9.06	1,078	9,767	47,410
Rose Geoffrey Beran	CHIEF COMMERCIAL OFFICER	Feb 22 '24	Sale	14.20	1,184	16,813	243,049
French Glendon E. III	PRESIDENT AND CEO	Feb 15 '24	Sale	14.60	20,000	292,000	1,121,344
Rose Geoffrey Beran	CHIEF COMMERCIAL OFFICER	Jan 22 '24	Sale	13.13	1,184	15,546	244,233
French Glendon E. III	PRESIDENT AND CEO	Jan 18 '24	Sale	12.77	10,000	127,700	1,141,344
Rose Geoffrey Beran	Chief Commercial Officer	Dec 22 '23	Sale	12.75	1,184	15,096	245,417

Pulmonx Corporation, a medical technology company, designs, develops, manufactures, and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in Europe, the Middle East, Africa, the Asia-Pacific, the United States, and internationally. Pulmonx Corporation was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. The company was incorporated in 1995 and is headquartered in Redwood City, California.